Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $23788.0.

  • Cumberland Pharmaceuticals' Capital Expenditures rose 5467.85% to $23788.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100187.0, marking a year-over-year decrease of 1122.19%. This contributed to the annual value of $66461.0 for FY2024, which is 7637.09% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Capital Expenditures of $23788.0 as of Q3 2025, which was up 5467.85% from $26486.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' Capital Expenditures' 5-year high stood at $137255.0 during Q2 2022, with a 5-year trough of -$153528.0 in Q4 2022.
  • In the last 5 years, Cumberland Pharmaceuticals' Capital Expenditures had a median value of $26986.0 in 2022 and averaged $34279.6.
  • Examining YoY changes over the last 5 years, Cumberland Pharmaceuticals' Capital Expenditures showed a top increase of 81060.17% in 2022 and a maximum decrease of 179700.45% in 2022.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Capital Expenditures stood at $9047.0 in 2021, then tumbled by 1797.0% to -$153528.0 in 2022, then soared by 131.7% to $48673.0 in 2023, then crashed by 95.31% to $2283.0 in 2024, then skyrocketed by 941.96% to $23788.0 in 2025.
  • Its Capital Expenditures stands at $23788.0 for Q3 2025, versus $26486.0 for Q2 2025 and $47630.0 for Q1 2025.